A clinical trial update was posted on August 26, 2026, for a study involving liraglutide. The trial, titled "GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry," is registered under identifier NCT07787936.
According to the current listing, the trial status is not yet recruiting. No phase designation was provided in the registration data. The registry is designed to examine GLP-1/GIP receptor agonists, a class that includes liraglutide, in the context of obesity-related heart failure with preserved ejection fraction, known as HFpEF.
No results, outcomes, or efficacy data have been posted for this trial at this stage. The listing reflects only the trial's registration and current recruitment status as of the update date. Further details on enrollment timelines, study design, or endpoints were not included in the available event data.
Liraglutide remains an approved compound. This update pertains only to a registry trial and does not reflect new safety or efficacy findings for liraglutide itself. Readers can consult the compound overview for additional background and context on liraglutide.